secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2025-07-28T23:59:59+00:00
Accession:  0001213900-25-068263
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Denali Capital Acquisition Corp. enters Amendment No. 2 to Merger Agreement with Semnur Pharmaceuticals
--------------------------------------------------------------------------------

- Amendment No. 2 signed on July 22, 2025 modifies Exchange Ratio and Merger Consideration definitions.
- Allows issuance of additional Semnur common shares pre-closing for private placement financing or advisor services.
- Maintains the 1.25-to-1 exchange ratio between Denali and Semnur shares.
- Parties include Denali Capital Acquisition Corp., Denali Merger Sub Inc., and Semnur Pharmaceuticals (Scilex subsidiary).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000121390025068263/0001213900-25-068263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000121390025068263/ea025050601-8k425_denali.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-068263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer